CRISPR Therapeutics AG: stock overview

CRSPNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$39.10

November 20, 2026Market cap $3.8B

What Ploutos Investor adds for CRISPR Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 11 fiscal years, from 2015
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 22% since Nov 2, 2026, when the 10-Q these figures come from was filed ($49.99 then, $39.10 on Nov 20, 2026). The figures date from before that move.10-Q

In short

CRISPR Therapeutics had revenue of $25M over the last 12 months and a net loss of $456M. Revenue grew by 37.3% a year on average over the last 5 years. It holds more cash than debt, by $1.7B. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 20, 2026.

Its SEC filings
Market cap
$3.8B
95.99M shares
P/E
–
Revenue, 12 months
$25M
+37.3% a year over 5 years
Net margin
-1,812.1%

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

-90.3% a year over 2 years

Fiscal years in figures

CRSP's revenue, profit, cash flow and dividend with each year-end price, from 2015 to 2022, 8 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $5.0B
$3.8B
Enterprise value 
$2.1B
P/E 
–
EV / EBIT 
–
EV / Revenue 
82.1
P/B 3-year median: 2.6
2.3
FCF yield 3-year median: -5.4%
–
Earnings yield 3-year median: -11.0%
–

Profitability

Operating margin 
-2,114.8%
Net margin 3-year median: -981.5%
-1,812.1%
ROIC 
-19.4%
ROIC, 5-year average 
-14.4%
ROE 
-25.2%

Growth

Revenue, yearly change 
-90.6%
EPS, yearly change 
–
FCF, yearly change 
–
Revenue, average a year 
+37.3%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$2.3B
Total debt 
$780M
Of which operating leases 
$193M
Net cash 
$1.7B
Net debt / EBITDA 
–
Interest cover 
–
Current ratio 
16.21

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+11.9%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
CRISPR Therapeutics AG
Exchange
NASDAQ
Industry (SIC)
2836 · Biological Products, (No Diagnostic Substances)
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
95.99M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do CRISPR Therapeutics's filings show?

These are CRISPR Therapeutics's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about CRSP

Didn't find what you were looking for?

Ask us
What is CRSP's market cap?

CRISPR Therapeutics AG's market cap is $3.8B, at a price of $39.10 on November 20, 2026 and 95.99M shares.

How much revenue does CRSP have?

CRISPR Therapeutics had revenue of $25M over the last 12 months. Over the last 5 years it changed by +37.3% a year on average.

Does CRSP pay a dividend?

No. CRISPR Therapeutics paid no regular dividend over the last 12 months.

Where do the figures come from?

From CRISPR Therapeutics AG's SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.